Cardiac Toxicity Associated with HCV Direct Antiviral Agents

Overview

Journal Mediterr J Hematol Infect Dis

Specialty Infectious Diseases

Date 2018 Nov 13

PMID 30416701

Citations 5

Authors

Claudio Ucciferri

Alessandro Occhionero

Jacopo Vecchiet

Katia Falasca

Affiliations

Soon will be listed here.

Citing Articles

ABT-333 (Dasabuvir) Increases Action Potential Duration and Provokes Early Afterdepolarizations in Canine Left Ventricular Cells via Inhibition of I.

Kovacs Z, Ovari J, Dienes C, Magyar J, Banyasz T, Nanasi P Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111245 PMC: 10143825. DOI: 10.3390/ph16040488.

Profiling the physiological pitfalls of anti-hepatitis C direct-acting agents in budding yeast.

Yahya G, Mohamed N, Pijuan J, Seleem N, Mosbah R, Hess S Microb Biotechnol. 2021; 14(5):2199-2213.

PMID: 34378349 PMC: 8449668. DOI: 10.1111/1751-7915.13904.

Host pharmacogenetic factors that may affect liver neoplasm incidence upon using direct-acting antivirals for treating hepatitis C infection.

Zidan A, Saad E, Ibrahim N, Hashem M, Mahmoud A, Hemeida A Heliyon. 2021; 7(5):e06908.

PMID: 34013078 PMC: 8113831. DOI: 10.1016/j.heliyon.2021.e06908.

Cardiac Injury Biomarkers and the Risk of Death in Patients with COVID-19: A Systematic Review and Meta-Analysis.

Alzahrani S, Al-Rabia M Cardiol Res Pract. 2021; 2021:9363569.

PMID: 33815838 PMC: 7977983. DOI: 10.1155/2021/9363569.

Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator.

Hurwitz S, McBrearty N, Arzumanyan A, Bichenkov E, Tao S, Bassit L Viruses. 2021; 13(1).

PMID: 33467678 PMC: 7830897. DOI: 10.3390/v13010114.

References

Ucciferri C, Mancino P, Vignale F, Vecchiet J, Falasca K . Induction with ribavirin in a relapsing patient with chronic HCV hepatitis. Braz J Infect Dis. 2012; 16(3):297-9. View

Maan R, van Tilborg M, Deterding K, Ramji A, van der Meer A, Wong F . Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol. 2016; 14(12):1821-1830.e6. DOI: 10.1016/j.cgh.2016.07.001. View

Renet S, Chaumais M, Antonini T, Zhao A, Thomas L, Savoure A . Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015; 149(6):1378-1380.e1. DOI: 10.1053/j.gastro.2015.07.051. View

Ahmad T, Yin P, Saffitz J, Pockros P, Lalezari J, Shiffman M . Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology. 2014; 62(2):409-16. DOI: 10.1002/hep.27488. View

Back D, Burger D . Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology. 2015; 149(6):1315-7. DOI: 10.1053/j.gastro.2015.09.031. View